Arcus Biosciences (RCUS) shares nine‑month 2025 financial results in 8-K

Rhea-AI Filing Summary

Arcus Biosciences, Inc. furnished a current report to share that it has issued a press release announcing its financial results for the nine months ended September 30, 2025. The company states that the full text of this results press release is provided as Exhibit 99.1 and is incorporated by reference. The information about these results is furnished under Item 2.02 of the report, meaning it is not treated as filed for liability purposes under the Exchange Act unless specifically incorporated into another filing.

false000172452100017245212025-10-282025-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________________

FORM 8-K

________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

________________________________________________________

Arcus Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

________________________________________________________

Delaware

001-38419

47-3898435

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3928 Point Eden Way

Hayward, California

94545

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 694-6200

(Former Name or Former Address, if Changed Since Last Report)

________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

RCUS

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On October 28, 2025, Arcus Biosciences, Inc. issued a press release announcing its financial results for the nine months ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press release dated October 28, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			ARCUS BIOSCIENCES, INC.
Date: October 28, 2025			By:			/s/ Terry Rosen, Ph. D.
						Terry Rosen, Ph.D.
						Chief Executive Officer (Principal Executive Officer)

FAQ

What did Arcus Biosciences (RCUS) disclose in this 8-K filing?

Arcus Biosciences disclosed that it issued a press release announcing its financial results for the nine months ended September 30, 2025, and furnished that release as Exhibit 99.1.

Which period do the Arcus Biosciences (RCUS) results in this filing cover?

The results referenced in this filing cover the nine-month period ended September 30, 2025.

Where can investors find the detailed financial results for Arcus Biosciences (RCUS)?

The detailed financial results are contained in the press release furnished as Exhibit 99.1, which is incorporated by reference in the report.

Is the Arcus Biosciences (RCUS) earnings press release considered filed with the SEC?

The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act unless specifically incorporated by reference elsewhere.

Who signed the Arcus Biosciences (RCUS) 8-K reporting the nine-month results?

The report was signed on behalf of Arcus Biosciences, Inc. by Terry Rosen, Ph.D., its Chief Executive Officer and principal executive officer.

What exhibits are included with the Arcus Biosciences (RCUS) 8-K?

The report includes Exhibit 99.1, a press release dated October 28, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.